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Abstract  43 
 44 
Within the hippocampus, the major somatostatin (SRIF) receptor subtype, the sst2A receptor, is 45 
localized at post-synaptic sites of the principal neurons where it modulates neuronal activity. 46 
Following agonist exposure, this receptor rapidly internalizes and recycles slowly through the 47 
trans-Golgi network. In epilepsy, a high and chronic release of somatostatin occurs which 48 
provokes, in both rat and human tissue, a decrease in the density of this inhibitory receptor at 49 
the cell surface. The insulin-regulated aminopeptidase (IRAP) is involved in vesicular trafficking 50 
and shares common regional distribution with the sst2A receptor. In addition, IRAP ligands 51 
display anticonvulsive properties. We therefore sought to assess by in vitro and in vivo 52 
experiments in hippocampal rat tissue whether IRAP ligands could regulate the trafficking of the 53 
sst2A receptor and, consequently, modulate limbic seizures. Using pharmacological and cell 54 
biological approaches, we demonstrate that IRAP ligands accelerate the recycling of the sst2A 55 
receptor that has internalized in neurons in vitro or in vivo. Most importantly, because IRAP 56 
ligands increase the density of this inhibitory receptor at the plasma membrane, they also 57 
potentiate the neuropeptide SRIF inhibitory effects on seizure activity. Our results further 58 
demonstrate that IRAP is a therapeutic target for the treatment of limbic seizures and possibly 59 
for other neurological conditions in which down-regulation of G protein-coupled receptors 60 
occurs.  61 
  62 
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Significance Statement 63 
 64 
The somatostatin type 2A receptor (sst2A) is localized on principal hippocampal neurons and 65 
displays anticonvulsant properties. Following agonist exposure, however, this receptor rapidly 66 
internalizes and recycles slowly. The insulin-regulated aminopeptidase (IRAP) is involved in 67 
vesicular trafficking and shares common regional distribution with the sst2A receptor. We 68 
therefore assessed by in vitro and in vivo experiments whether IRAP could regulate the 69 
trafficking of this receptor. We demonstrate that IRAP ligands accelerate sst2A recycling in 70 
hippocampal neurons. Because IRAP ligands increase the density of sst2A receptors at the 71 
plasma membrane, they also potentiate the effects of this inhibitory receptor on seizure activity. 72 
Our results further demonstrate that IRAP is a therapeutic target for the treatment of limbic 73 
seizures.74 
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 Introduction  75 
 76 
The somatostatin (SRIF) type 2A receptor (sst2A) mediates SRIF inhibitory effects on cell 77 
excitability (Peineau et al., 2003; Olias et al., 2004; Bassant et al., 2005) and displays 78 
anticonvulsant properties (Vezzani and Hoyer, 1999; Tallent and Qiu, 2008; Clynen et al., 2014; 79 
Dobolyi et al., 2014). Like many GPCRs, sst2A receptors rapidly internalize (Dournaud et al., 80 
1998; Csaba et al., 2001; Csaba et al., 2003; Stumm et al., 2004; Csaba et al., 2012) and are 81 
then specifically targeted to a perinuclear/trans-Golgi network (TGN) compartment, bypassing 82 
the late endosomal compartment and the degradative pathway (Csaba et al., 2007; Lelouvier et 83 
al., 2008). Afterwards they slowly recycle to the plasma membrane of both cell bodies and 84 
dendrites. Interestingly, this particular recycling route undertaken by the sst2A receptor shares 85 
common pathways with the glucose transporter 4 (GLUT4) (Leto and Saltiel, 2012). A key 86 
regulator of GLUT4 storage vesicles is the insulin-regulated aminopeptidase (IRAP), a type II 87 
membrane protein (Chai et al., 2004; Albiston et al., 2007; Vanderheyden, 2009; Wright and 88 
Harding, 2011). In the basal state, IRAP is located principally in an intracellular compartment 89 
with GLUT4, and these proteins move to the cell surface identically in response to insulin (Keller, 90 
2003). In addition to its aminopeptidase activity involved in peptide hormone processing, IRAP 91 
also acts as a receptor for the endogenous ligands angiotensin IV (Ang IV) and LVV-Hemorphin 92 
7 (LVV-H7). IRAP ligands are on the one hand competitive inhibitors of the enzymatic activity of 93 
IRAP and on the other hand regulators of its trafficking (Albiston et al., 2007). The extracellular 94 
part of IRAP contains the aminopeptidase activity while its intracellular domain interacts with 95 
cytosolic proteins that contribute to GLUT4 vesicles retention and translocation to the plasma 96 
membrane, however the mechanisms involved in this latter process remain to be demonstrated 97 
(Albiston et al., 2007). 98 
 Although the memory- and cognitive-enhancing effects of IRAP ligands are well 99 
established (Albiston et al., 2003; Albiston et al., 2011), the role of IRAP in the central nervous 100 
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system is yet to be fully elucidated. Most interestingly, IRAP ligands display anticonvulsive 101 
activities in different animal models (Tchekalarova et al., 2001; Tchekalarova et al., 2004; 102 
Stragier et al., 2006; Loyens et al., 2011). In accordance with these central actions, IRAP was 103 
found to be highly expressed in brain areas associated with cognition and epilepsy (Fernando et 104 
al., 2005), regions that also displayed the highest densities of sst2A receptor immunoreactivity 105 
(Dournaud et al., 1996; Schindler et al., 1997; Dournaud et al., 1998). At the cellular level, IRAP 106 
immunoreactivity in neurons is associated with the trans-Golgi apparatus and vesicular 107 
structures in the proximity of the Golgi cisternae (Fernando et al., 2007), a location remarkably 108 
comparable to that of internalized sst2A receptors before recycling (Csaba et al., 2007; Lelouvier 109 
et al., 2008). Because IRAP shares common distribution with the sst2A receptor and is involved 110 
in vesicular trafficking, we sought to assess by in vitro and in vivo experiments whether IRAP 111 
could regulate the trafficking of the sst2A receptor and, consequently, modulate its 112 
anticonvulsant actions.  113 
114 
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Material and Methods  115 
 116 
Animals. Experimental procedures were performed using adult male Wistar rats (Charles 117 
River Laboratories). All efforts were made to reduce the number of animals used and any 118 
distress caused by the procedures is in accordance with the European Communities Council 119 
Directive of September 22, 2010 (2010/63/UE) and complying with the guidelines of Inserm, the 120 
ethics committees on animal experiments of Paris Diderot University, the Vrije Universiteit 121 
Brussel and the University of Crete. Accordingly, the number of animals in our study was kept to 122 
the necessary minimum. 123 
 124 
Antibodies. The endogenous sst2A receptor was immunolocalized using a rabbit 125 
monoclonal antibody (3582-1, Epitomics; 1:1000). This antibody is directed towards residues 126 
355–369 of the human sst2A receptor. This sequence is identical in mouse, rat, and human 127 
sst2A. Endogenous IRAP was detected using a mouse monoclonal antibody (9876-3E1, Cell 128 
Signaling; 1:200) directed against a fusion protein corresponding to the amino terminus of rat 129 
IRAP. A sheep polyclonal antibody was used to detect the trans-Golgi network (TGN) specific 130 
integral membrane protein (TGN38) (PA1-84496, Thermo Scientific; 1:800). Secondary 131 
antibodies used were Alexa Fluor 488 (A488)-conjugated donkey anti-rabbit (1:500; Life 132 
Technologies, Molecular Probes) or Cyanine 3 (Cy3)-conjugated donkey anti rabbit (1:500; 133 
Jackson ImmunoResearch), Cy3-conjugated donkey anti-mouse (1:500; Jackson 134 
ImmunoResearch) or A488-conjugated donkey anti-mouse (1:500; Life Technologies, Molecular 135 
Probes), and Alexa Fluor 633 (A633)-conjugated donkey anti-sheep (1:500; Life Technologies, 136 
Molecular Probes) to immunolocalize sst2A receptor, IRAP and TGN38, respectively. For 137 
chromogenic detection of sst2A receptor and IRAP, biotinylated goat anti-rabbit and anti-mouse 138 
antibodies (1:300, Vector Laboratories) were used, respectively. 139 
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 140 
 Stereotaxic injection of octreotide. Rats under isoflurane anesthesia were mounted on a 141 
stereotaxic frame and injected into the dorsal hippocampus (coordinates: 2.8 mm posterior; 1.4 142 
mm lateral; 3.2 mm ventral from Bregma) with octreotide (OCT; gift from Novartis Pharma AG) 143 
as previously described (Csaba et al., 2007). After 3h of survival, rats were deeply anesthetized 144 
with sodium pentobarbital (60 mg/kg i.p.) and perfused through the ascending aorta with 400 ml 145 
of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB). Brains were cryoprotected, 146 
frozen in liquid isopentane at -45°C and sectioned in the coronal plane at a thickness of 30 μm 147 
as previously described (Csaba et al., 2007). 148 
 149 
 Immunohistochemistry. Brain sections at the level of the dorsal hippocampus were 150 
selected for chromogenic and immunofluorescent labeling. For chromogenic labeling, 151 
endogenous peroxidase activity was first quenched by 0.3% H2O2 in 0.01 M phosphate-buffered 152 
saline, pH 7.4 (PBS) for 30 min at room temperature (RT), washed in PBS, incubated in PBS 153 
with 5% normal goat serum (NGS; Sigma-Aldrich) and 0.3% Triton X-100 for 30 min at RT, 154 
incubated with primary antibodies diluted in PBS with 1% NGS and 0.3% Triton X-100 overnight 155 
at RT, rinsed in PBS, incubated in biotinylated secondary antibodies diluted in PBS with 3% 156 
NGS and 0.3% Triton X-100 for 1 h at RT, washed in PBS, and incubated in avidin-biotinylated 157 
horseradish peroxidase complex (ABC; Vector Laboratories) diluted in PBS for 90 min at RT. 158 
Peroxidase activity was revealed with 0.05% of 3,3'-diaminobenzidine (DAB; Sigma-Aldrich) in 159 
0.05 M Tris buffer, pH 7.6 (TB), in the presence of hydrogen peroxide (0.0048%). The reaction 160 
was stopped by several washes in TB. Sections were mounted on gelatin-coated slides, 161 
dehydrated in graded ethanols, delipidated in xylene and coverslipped with Permount (Fisher 162 
Scientific) for light microscopic observation. For immunofluorescent labeling, sections were 163 
preincubated in PBS with 5% normal donkey serum (NDS, Sigma-Aldrich) and 0.3% Triton X-164 
100 for 30 min at RT, incubated in primary antibodies diluted in PBS with 1% NDS and 0.3% 165 
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Triton X-100 overnight at RT, rinsed in PBS, and incubated in fluorescent secondary antibodies 166 
diluted in PBS with 3% NDS and 0.3% Triton X-100 for 1 h at RT. Finally, sections were rinsed in 167 
PBS, mounted on glass slides and coverslipped with Fluoromount (Southern Biotech) for 168 
confocal microscopic analysis. 169 
 170 
Hippocampal cell cultures. Hippocampi were dissected from 18-day-old embryo Wistar 171 
rat brains and dissociated in HBSS with 0.25% trypsin and 0.1% DNase 1. Hippocampal 172 
neurons were plated on glass coverslips previously coated with gelatin and poly-L-lysine. 173 
Neurons were grown in Neurobasal medium (Invitrogen) supplemented with B27 and glutamine 174 
(Invitrogen) and maintained in an incubator at 37°C in a 95% air/5% CO2 humidified atmosphere. 175 
All experiments were carried out at 12-13 days in vitro. 176 
 177 
In vitro pharmacological treatment. For time-course experiments of sst2A receptor 178 
internalization, neurons were treated with 1 μM of the sst2A receptor agonist octreotide (OCT) in 179 
Neurobasal medium for 5, 10, 15 and 20 min at 37°C. For time-course experiments of sst2A 180 
receptor recycling, neurons were pretreated with 1 μM Ang IV (or PBS as control) in Neurobasal 181 
medium for 60 min at 37°C, followed by addition of 1 μM OCT or SRIF (Sigma-Aldrich) for 20 182 
min. After rinsing, neurons were treated with 1 μM Ang IV (or PBS as control) in Neurobasal 183 
medium for 15, 30, 45, 60, 120 and 180 min at 37°C. Additional control conditions included 184 
neurons pretreated with 1 μM Ang IV (or PBS) without subsequent OCT or SRIF treatment 185 
(Control w/o OCT; Control w/o agonist). At the end of incubation times, neurons were fixed with 186 
4% paraformaldehyde supplemented with 4% sucrose in PB for 20 min at RT. 187 
 188 
shRNA lentiviral transduction. Rat IRAP expression was inhibited in cultured 189 
hippocampal cells using SMART vector 2.0 PGK-TurboGFP shRNA particles according to 190 
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manufacturer’s protocols (Thermo Scientific, Dharmacon). Three predesigned individual IRAP-191 
gene specific shRNA lentiviral particles were obtained from Dharmacon and provided as ready-192 
to-use lentiviral particles (SH06-093146-01-10, SH06-093146-02-10 and SH06-093146-03-10). 193 
The shRNA target sequences were as follows: IRAP LV-shRNA1: GATTGCTACAAACGGGAAA, 194 
IRAP LV-shRNA2: AAGTTGGAGCAAGAACCGA and IRAP LV-shRNA3: 195 
GATTAGTGACCAGAGTACA. SMART vector 2.0 Non-targeting PGK-Turbo GFP particles (S06-196 
0050000-01) was used as control (NT LV-shRNA; TGGTTTACATGTTGTGTGA). Hippocampal 197 
cells were transduced immediately after dissociation for 1 h at 37°C (at a multiplicity of infection-198 
moi-of 10) and used for sst2A receptor recycling experiments at 12-13 days in vitro. Based on 199 
TurboGFP expression, neuronal efficiency of transduction was 38.3% for the IRAP LV-shRNA1, 200 
32.3% for the IRAP LV-shRNA2, 49.1% for the IRAP LV-shRNA3 and 45.0% for the NT LV-201 
shRNA.  202 
  203 
Immunocytochemistry. Cells were washed in PBS and incubated 30 min in PBS with 5% 204 
NDS and 0.1% Triton X-100. Primary antibodies were diluted in PBS with 1% NDS and 0.1% 205 
Triton X-100 and incubated overnight at 4°C. Neurons were washed in PBS and subsequently 206 
incubated with secondary antibodies diluted in PBS with 1% NDS and 0.1 % Triton X-100 for 1 h 207 
at RT. Finally, coverslips were washed in PBS and mounted with Fluoromount (Southern 208 
Biotech) for confocal microscopic analysis. 209 
 210 
Confocal microscopy. Immunofluorescent sections were analyzed using a Leica TCS 211 
SP8 confocal scanning system (Leica Microsystems) equipped with 488-nm Ar, 561-nm DPSS 212 
and 633-nm HeNe lasers or a Zeiss LSM 5 Exciter confocal scanning system (Carl Zeiss) with 213 
488-nm Ar, 543-nm HeNe and 633-nm HeNe lasers. Eight-bit digital images were collected from 214 
a single optical plane using a 63x HC PL APO CS2 oil-immersion Leica objective (numerical 215 
aperture 1.40) or a 63x Plan-Apochromat oil-immersion Zeiss lens (numerical aperture 1.4). For 216 
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each optical section, double- or triple-fluorescence images were acquired in sequential mode to 217 
avoid potential contamination by linkage specific fluorescence emission cross-talk. Settings for 218 
laser intensity, beam expander, pinhole (1 Airy unit), range property of emission window, 219 
electronic zoom, gain and offset of photomultiplicator, field format, scanning speed were 220 
optimized initially and held constant throughout the study so that all sections were digitized 221 
under the same conditions.  222 
 223 
Quantitative analysis of immunofluorescence. To assess the extent of IRAP knockdown, 224 
images of IRAP immunofluorescence from neuronal cell bodies were collected from a single 225 
optical plane using a 63x Plan-Apochromat oil-immersion Zeiss lens (numerical aperture 1.4). 226 
Images were segmented using identical threshold values, and integrated signal density was 227 
measured using the ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of 228 
Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2014.). This parameter, 229 
corresponding to the intensity of the immunofluorescence staining, was measured in an average 230 
of 30 neurons/group from 3 independent experiments. Mean values for the 4 experimental 231 
groups (IRAP LV-shRNA1-3 constructs and NT LV-shRNA control) were calculated and 232 
statistically analyzed. 233 
To quantify sst2A receptor immunoreactivity at the plasma membrane, images of sst2A 234 
receptor and TGN38 immunofluorescence from neuronal cell bodies were acquired from a single 235 
optical plane using a 63x Plan-Apochromat oil-immersion Zeiss lens (numerical aperture 1.4). 236 
The z-axis level was selected where the TGN38-labeled trans-Golgi network was clearly 237 
identified and the sst2A receptor labeling at the plasma membrane was identified as a line-like 238 
ring in the green channel around the TGN38 labeling of the red channel (Fig. 6a). A 1 μm wide 239 
band containing the line-like sst2A receptor labeling was defined and the average pixel intensity, 240 
corresponding to the intensity of the immunofluorescent staining, was measured within the 241 
selection using the ImageJ software in an average of 30 neurons/group from 3 independent 242 
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experiments. Three sets of experiments were analyzed. One set contained 14 groups of the 243 
time-course experiments of sst2A receptor recycling (Control w/o OCT; 15, 30, 45, 60, 120 and 244 
180 min after OCT washout with or without Ang IV). The second set contained 6 groups (Control 245 
w/o agonist; 45 min after OCT washout and 45 min after SRIF washout with or without Ang IV). 246 
The third set contained 4 groups of the lentiviral shRNA experiments (IRAP LV-shRNA1-3 247 
constructs and NT LV-shRNA control; 45 min after OCT washout). Mean values for the 248 
experimental groups were calculated and statistically analyzed. 249 
 250 
Binding of IRAP ligands to sst2A receptor in stably transfected CHO-K1 cells. Chinese 251 
Hamster Ovary (CHO-K1) cells stably transfected with the sst2A receptor were plated in 24-well 252 
plates (Becton Dickinson) and cultured until confluence in Dulbecco’s modified essential medium 253 
(DMEM) supplemented with L-glutamine (2 mM), 2% (v/v) of a stock solution containing 5000 254 
IU/ml penicillin and 5000 µg/ml streptomycine (Invitrogen), 1% (v/v) of a stock solution 255 
containing non-essential amino acids, 1 mM sodium pyruvate and 10% (v/v) fetal bovine serum 256 
(Invitrogen). Before the experiment, cells were washed twice with 500 µl per well of Krebs buffer 257 
(20 mM, CaCl2, 2.7 mM KCl, 2.1 mM MgCl2, 137 mM NaCl and 20 mM HEPES, pH 7.4) at RT. 258 
Incubations were carried out for 45 min at 37°C in a final volume of 500 µl per well consisting of 259 
400 µl Krebs buffer, 50 µl of increasing concentrations of Ang IV or LVV-H7 (10-9 M – 10-5 M) 260 
and 50 µl 125I-labeled SRIF (0.5 nM). At the end of the incubation period, the plates were placed 261 
on ice and washed three times with ice-cold PBS. For whole-cell binding (i.e. without distinction 262 
between surface-binding and intracellular accumulation of the radioligand) cells were then 263 
solubilized by addition of 300 µl NaOH (1 M). After 60 min treatment at RT, solutes were 264 
transferred in scintillation vials. Three ml of scintillation liquid (Optiphase Hisafe, Perkin Elmer) 265 
was added and the remaining radioactivity was measured in a γ-counter (Perkin Elmer). The 266 
experiments were repeated four times and results are shown in a compilation graph as the 267 
percentage of 125I-labeled SRIF binding to sst2A receptors, in the presence of Ang IV or LVV-H7. 268 
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 269 
Focal pilocarpine-induced seizures in rats.  270 
Surgery. Adult male Wistar rats (275-300 g) were anaesthetized with a mixture of 271 
ketamine and diazepam (start dose: 90:4.5 mg/kg), placed on a stereotaxic frame and implanted 272 
with a microdialysis guide cannula (CMA/12, CMA Microdialysis/AB) above the left (or right) 273 
hippocampus at flat skull coordinates: A -5.6 mm, L ±4.6 mm, V −4.6 mm relative to Bregma. For 274 
experiments with intrahippocampal electroencephalographic (EEG) recording, the guide cannula 275 
was customized by gluing an insulated electrode wire to the guide cannula and exposing it over 276 
a length of 0.5 mm beyond the tip of the guide cannula. The guide was secured to the skull with 277 
dental cement. For experiments with intrahippocampal EEG recordings, rats were s.c. implanted 278 
with a sterilized radiotelemetric transmitter (F20-EET, Data Sciences International) which was 279 
then subcutaneously tunneled to the intrahippocampal measuring electrode and the reference 280 
electrode which was attached to the skull with a stainless steel screw implanted 1 mm anterior of 281 
lambda. Postoperative analgesia was provided by s.c. ketoprofen (3mg/kg). A concentric 282 
microdialysis probe (3 mm length, CMA/12 Elite, CMA Microdialysis/AB) was inserted into the 283 
guide cannula. Following transfer of the animals to the microdialysis cage, the microdialysis 284 
probe was perfused with a modified Ringer’s solution (147 mM NaCl, 4 mM KCl, 2.3 mM CaCl2) 285 
at a flow rate of 2 μl/min using a CMA infusion pump (CMA120, CMA Microdialysis/AB). Rats 286 
had free access to food and water. Confirmation of unilateral probe placement was established 287 
at the end of each experiment on 50 μm brain slices prepared on a cryostat (Reichtert-Jung 288 
1206, Cambridge Instruments).  289 
Microdialysis and seizure severity assessment. All microdialysis experiments were 290 
performed on the day following surgery. A microdialysis flow rate of 2 µl/min was maintained 291 
throughout the pilocarpine experiments. Seizures were evoked by adding 10 mM pilocarpine to 292 
the perfusion liquid during two 20 min sampling periods. Animals were rated on a seizure 293 
severity scale based on Racine’s scale which was adopted to include behavioral changes 294 
  13
observed in the focal pilocarpine model: (0) normal non-epileptic activity; (1) stereotypical mouth 295 
and facial movements, wet dog shakes; (2) head nodding, tremor, staring; (3) forelimb clonus, 296 
forelimb extension; (4) rearing, tonic-clonic activity; (5) falling (Meurs et al. 2008). The total 297 
seizure severity score (TSSS) was the sum of the highest seizure severity score (SSS) observed 298 
in each of the seven collection periods following the start of pilocarpine administration, and was 299 
used as a measure of seizure severity. Additional experiments were performed in rats implanted 300 
with an intrahippocampal EEG recording electrode and radiotelemetric transmitter. These rats 301 
were placed in a microdialysis bowl equipped with an EEG monitoring unit with radiotelemetric 302 
receiver (PhysioTel RPC-1, Data Sciences International) coupled to a Notocord-hem Evolution 303 
acquisition system (Notocord). The intrahippocampal EEG was sampled at 100 Hz during 304 
microdialysis sampling and the total EEG seizure duration and latency until the first EEG seizure 305 
was determined. The observed behavioral seizures were correlated to EEG seizures by linear 306 
regression analysis. Protocols differed between experimental groups as detailed below.  307 
Effect of intra-hippocampal Ang IV and LVV-H7 in the focal pilocarpine model. Following 308 
the collection of 8 baseline samples 0 µM, 1 µM or 10 µM Ang IV or LVV-H7 were perfused 309 
through the microdialysis probe from the 9th sample collection period onwards. Pilocarpine was 310 
co-perfused at a concentration of 10 mM during the 13th and 14th sample collection periods. 311 
Hippocampal dialysate samples were subsequently collected for an additional 5 collection 312 
periods.  313 
Involvement of the sst2A receptor in the anticonvulsive effects of Ang IV and LVV-H7. 314 
The involvement of the sst2A receptor in the observed effects of Ang IV and LVV-H7 was 315 
investigated in experiments with collection of 6 baseline samples, followed by perfusion of the 316 
microdialysis probe with 0.1 µM cyanamid 154806 (Sigma Aldrich) or 0.1 µM BIM-23627 (kindly 317 
provided by Dr. Michael D. Culler, Ipsen Pharma) from the 7th sample collection period onwards. 318 
From the 9th sample collection period onwards, 0 µM, 10 µM and 15 µM Ang IV or 10 µM LVV-319 
H7 were added to the perfusion liquid. Pilocarpine was co-perfused at a concentration of 10 mM 320 
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during the 13th and 14th sample collection periods. Hippocampal dialysate samples were 321 
collected for an additional 5 collection periods. 322 
Selectivity of the effects of Ang IV and LVV-H7 in the focal pilocarpine model. The 323 
involvement of the AT1 receptor in the observed effects of Ang IV and the involvement of the µ/κ 324 
opioid receptors in the anticonvulsant effects of LVV-H7 was investigated in experiments 325 
according to exactly the same microdialysis protocol as described above for the sst2A receptors. 326 
AT1 receptor antagonist candesartan and µ/κ opioid receptor antagonist naltrexone were used 327 
at 0.1 µM concentration. 328 
Potentiation of the anticonvulsive effect of SRIF by Ang IV in the focal pilocarpine model. 329 
The effect of Ang IV on the anticonvulsive effect of SRIF was further investigated according to 330 
the previously described microdialysis protocol. Ang IV and SRIF were used in a subthreshold 331 
concentration that did not affect pilocarpine-induced seizures as such. Essentially we used 1 µM 332 
for Ang IV and 0.1 µM for SRIF. Ang IV and SRIF were perfused through the microdialysis 333 
probe, either alone or in combination, from the 9th sample collection period onwards. Pilocarpine 334 
was co-perfused at a concentration of 10 mM during the 13th and 14th sample collection periods. 335 
Hippocampal dialysate samples were subsequently collected for an additional 5 collection 336 
periods. Two rats treated with the combination of Ang IV and SRIF did not show EEG seizure 337 
activity and were excluded for analysis of EEG seizure latency. 338 
 339 
Effects of IRAP ligands on rat hippocampal SRIF. Stereotactic surgery for bilateral probe 340 
implantation in left and right hippocampus was performed as described above for the unilateral 341 
intra-hippocampal probe implantation. Microdialysis probes (3 mm length, CMA/12 Elite, CMA 342 
Microdialysis/AB) were continuously perfused with artificial cerebrospinal fluid (aCSF, 125 mM 343 
NaCl, 2.5 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 3.5 mM NaH2PO4, 0.2 mM ascorbic acid, 344 
0.025% bovine serum albumin, pH 7.4) at a flow rate of 1.0 μl/min using a microdialysis pump 345 
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(CMA120, CMA Microdialysis/AB) following transfer of the animals to a microdialysis cage with 346 
free access to food and water. The day following surgery, samples from the two bilateral probes 347 
were collected every 30 min and pooled yielding a total volume of 60 µl. At the beginning of each 348 
experiment, samples were collected under baseline conditions, corresponding to perfusion of the 349 
probe with aCSF alone. Then 10 µM Ang IV or 10 µM LVV-H7 was added to the perfusion liquid 350 
for the remainder of the experiment. SRIF dialysate content was determined using a 351 
radioimmuno assay (RIA) with [125I]-Tyr11-Somatostatin (IM 161, Amersham) and a SRIF 352 
antibody (N 1611, Amersham) raised against cyclic SRIF. A standard curve was prepared using 353 
[125I]-Tyr11-somatostatin (6000 cpm, 2200 Ci/mmol), the antibody (final dilution 1/3000) and 354 
synthetic cyclic SRIF in a 0.8 ml solution containing 50 mM sodium phosphate, 10 mM EDTA 355 
and 0.3% bovine serum albumin (pH 7.4). The radioactivity was counted with a γ-counter. 356 
Results were read from the standard curve and the minimal detectable dose was 39.3 pg/100 µl. 357 
Confirmation of bilateral probe placement was again established at the end of each experiment 358 
on 50 μm brain slices prepared on a cryostat (Reichtert-Jung 1206, Cambridge Instruments). 359 
 360 
Electron microscopy. For electron microscopic detection of the sst2A receptor in 361 
pilocarpine-treated rats in the presence or absence of Ang IV, a similar microdialysis protocol as 362 
described above under “Effect of intra-hippocampal Ang IV and LVV-H7 in the focal pilocarpine 363 
model “ was used. However, after the 15th collection period (time point where maximal seizures 364 
are detected), rats were deeply anesthetized with sodium pentobarbital (60 mg/kg i.p.) and 365 
perfused through the ascending aorta with 100 ml of saline followed by 400 ml of ice-cold 4% 366 
paraformaldehyde and 0.05% glutaraldehyde in PB. Brains were post-fixed overnight in 4% 367 
paraformaldehyde at 4°C. Coronal sections were cut on a vibratome at 70 µm and collected in 368 
PBS. Sections within 1 mm of the microdialysis probe were selected and equilibrated in 25% 369 
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sucrose and 10% glycerol in 0.05 M PB, frozen rapidly in isopentane cooled in liquid nitrogen, 370 
and thawed in PBS at RT.  371 
For pre-embedding immunocytochemistry, sections were preincubated for 30 min in 5% 372 
NGS in PBS. Sections were then incubated overnight at RT in rabbit anti-sst2A receptor 373 
antibody (1:1000) diluted in PBS containing 1% NGS. After washing in PBS, sections were 374 
incubated for 120 min in Nanogold®-conjugated goat anti rabbit IgG (1:100; Nanoprobes) diluted 375 
in PBS containing 2% of bovine serum albumin-c and 0.2% of cold water fish gelatin. Sections 376 
were washed in PBS and post-fixed in 1% glutaraldehyde in PBS for 10 min. After washings in 377 
PBS and 0.1 M sodium acetate buffer, pH 7.0, sst2A receptor immunogold labeling was 378 
intensified using a silver enhancement kit (HQ Silver; Nanoprobes) for 5-10 min in the dark at 379 
RT. After washings in acetate buffer and in PB, sections were post-fixed in 1% osmium tetroxide 380 
in PB for 10 min at RT. After washings in PB, they were dehydrated in an ascending series of 381 
ethanol, which included 1% uranyl acetate in 70% ethanol. They were then treated with 382 
propylene oxide twice for 10 min, equilibrated overnight in Durcupan ACM (Fluka), mounted on 383 
glass slides and cured at 60°C for 48 h. Areas of interest were cut out from the slide and glued 384 
to blank cylinders of resin. Blocks were cut in semithin sections (1 µm) and then in ultrathin 385 
sections on a Reichert Ultracut S microtome. Ultrathin sections were collected on pioloform-386 
coated single-slot grids. Sections were stained with lead citrate and examined with a Philips 387 
CM120 electron microscope equipped with Morada Soft Imaging System (Olympus Soft Imaging 388 
Solutions). On the ultrathin sections, only areas at the surface of the vibratome sections were 389 
analyzed. The acquired images were equally adjusted for brightness and contrast, and 390 
composite illustrations were built in Adobe Photoshop CS3 (Adobe Systems). 391 
 392 
Quantification of electron microscopic immunocytochemistry. The subcellular distribution 393 
of sst2A receptor in CA1 pyramidal cell dendrites was analyzed using the Measure command 394 
and Cell counter plugin of ImageJ in 3 control and 3 Ang IV-treated rats. An average of 10 395 
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dendrites per animal was analyzed. The length of the plasma membrane and the caliber of 396 
dendrites (expressed in cross-sectional surface; μm2) were measured. The sst2A receptor 397 
immunoparticles were identified and counted in association with the plasma membrane and in 398 
the intracellular compartment. Results were expressed as: (1) the percentage of 399 
immunoparticles associated with the plasma membrane and the intracellular compartment (%); 400 
(2) density of immunoparticles per membrane length (μm) or cytoplasmic surface (μm2).  401 
 402 
Data analysis. Statistical analysis was performed using GraphPad Prism 4.0 (GraphPad 403 
Prism Software Inc.). Statistical tests applied to the data are indicated in the legends of the 404 
figures. Differences were considered to be significant at p < 0.05. All data in text and figures are 405 
presented as mean±S.E.M.  406 
407 
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Results 408 
 409 
Sst2A receptor-expressing neuronal cells colocalize with IRAP in the rat 410 
hippocampal formation  411 
The sst2A receptor and IRAP display similar regional expression patterns (Fig. 1a,c). 412 
Whereas IRAP imunoreactivity was localized in the principal cells of CA1-3 and dentate gyrus 413 
(Fig. 1c,d), sst2A receptor immunoreactivity is distributed in both dendritic fields and principal 414 
cells of the hippocampus (Fig. 1a,d inset) (Csaba et al., 2001; Csaba et al., 2007). In vivo 415 
internalization of the receptor through intra-hippocampal octreotide (OCT) injections revealed 416 
sst2A receptor-expressing cell bodies (Fig. 1b,e), as previously reported (Csaba et al., 2001; 417 
Csaba et al., 2007). Double-labeling experiments demonstrated that all hippocampal sst2A 418 
receptor-positive neurons displayed IRAP immunoreactivity (Fig. 1e-g). 419 
 420 
Internalized sst2A receptors are targeted to IRAP-positive vesicles in neurons 421 
IRAP and sst2A receptor sub-cellular distribution was then studied in cultured rat 422 
hippocampal neurons to analyze whether both proteins could colocalize during receptor 423 
internalization and recycling. In non-treated control cells (Fig. 2), a predominant plasma 424 
membrane distribution of the endogenous sst2A receptor was detected at the surface of 425 
perikarya and dendrites, confirming our former results (Csaba et al., 2001; Csaba et al., 2007; 426 
Lelouvier et al., 2008). In accordance with earlier studies (Fernando et al., 2005; Fernando et al., 427 
2007), endogenous IRAP immunoreactivity was mainly confined to intracytoplasmic granules in 428 
the perikarya and was also detected in proximal dendrites (Fig. 2). Finally, in the neuronal cell 429 
body, IRAP-positive vesicles were located in a perinuclear compartment and overlapped with the 430 
trans-Golgi marker TGN38, as previously reported (Fernando et al., 2007; Fernando et al., 2008) 431 
(Fig. 2). In agreement with these latter studies, a faint IRAP signal was also apparent at the 432 
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plasma membrane. Therefore, little colocalization between sst2A receptor and IRAP was 433 
observed in control conditions.  434 
After 5-10 min of agonist stimulation with 1 µM OCT, endogenous sst2A receptors were 435 
no longer present at the cell surface, and bright fluorescent accumulations appeared in the 436 
cytoplasm of perikarya and dendrites (Fig. 2). The same redistribution of sst2A immunoreactivity 437 
was observed after 1 µM SRIF treatment (data not shown), as previously reported (Lelouvier et 438 
al., 2008). Very interestingly, extensive colocalization between sst2A receptor and IRAP 439 
immunoreactivity was detected both in perikarya and proximal dendrites between 5 and 20 min 440 
following the beginning of the OCT treatment, as shown by the yellow pseudocolor signal 441 
present in the overlaid images (Figs. 2, 3). This indicates that internalized receptors are 442 
massively targeted to IRAP-positive intracellular compartments in hippocampal neurons. This 443 
colocalization gradually decreased in time as the receptor recycled back to the plasma 444 
membrane (Fig. 4). 445 
 446 
IRAP ligand accelerates sst2A receptor recycling in hippocampal neurons 447 
Next, we performed kinetic experiments to analyze whether IRAP ligand Ang IV could 448 
impact on the trafficking and recycling of endogenous sst2A receptor following agonist-induced 449 
internalization (Fig. 5). In hippocampal neurons treated with OCT but in the absence of Ang IV, 450 
reappearance of sst2A receptors at the plasma membrane of the cell body was first evident 30 451 
min after OCT washout. Three hours after OCT stimulation, receptor distribution and density 452 
were similar to control conditions, i.e. receptors were localized at the plasma membrane of both 453 
the cell body and dendrites. 454 
In hippocampal neurons treated with OCT but in the presence of Ang IV, we observed a 455 
shift of the reappearance of the sst2A receptors at the plasma membrane (Figs. 5, 6). At 30, 45 456 
and 60 min after OCT washout, the amount of membrane-associated receptors was significantly 457 
higher in Ang IV-treated neurons (OCT + Ang IV) than in respective controls (OCT + PBS) (30 458 
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min: +69%, 45 min: +82%, 60 min: +64%; Fig. 6b). No difference was observed in the recycling 459 
kinetics of the sst2A receptor following SRIF- or OCT-induced internalization. Notably, Ang IV 460 
treatment resulted in a faster sst2A receptor recycling with both agonists (Fig. 6b). Interestingly, 461 
within the Ang IV-treated group, we observed that 45 and 60 min after OCT washout the density 462 
of receptors at the plasma membrane was significantly higher than in cells not treated with OCT 463 
(Ang IV without OCT) (45 min: +33%, p < 0.001; 60 min: +18%, p < 0.01; Dunnett's Multiple 464 
Comparison Test; Fig. 6b). In cells treated with OCT in the absence of Ang IV, this phenomenon 465 
was also apparent but only 120 min after OCT washout (+16% vs. PBS without OCT, p < 0.001, 466 
Dunnett's Multiple Comparison Test; Fig. 6b). These data suggest that massive pools of sst2A 467 
receptors are first targeted from the perinuclear recycling compartment to the plasma membrane 468 
of the cell body, before diffusing to the dendritic fields along the membranes, and this process is 469 
accelerated in Ang IV-treated neurons. Together, these results suggest that the IRAP ligand has 470 
shortened the recycling time of internalized sst2A receptors to the plasma membrane.  471 
 472 
IRAP ligands do not bind the sst2A receptor 473 
To analyze whether the Ang IV effects on sst2A receptor recycling could be due to 474 
putative cross-reaction between the IRAP ligands and the sst2A receptor, cultured hippocampal 475 
neurons were treated with 1 µM Ang IV or LVV-H7 and fixed 20 to 180 min thereafter for 476 
immunoreactive detection of the endogenous sst2A receptor. Neither Ang IV nor LVV-H7 did 477 
change the distribution of sst2A receptor immunoreactivity (data not shown). The possible direct 478 
interaction between IRAP ligands and the sst2A receptor was also investigated in CHO-K1 cells 479 
stably transfected with the sst2A receptor incubated with increasing concentrations of Ang IV 480 
and LVV-H7. The total percentage of 125I-labeled SRIF binding to sst2A receptor did not change 481 
throughout the whole experiment, in the presence of either Ang IV or LVV-H7 (Fig. 7). Together, 482 
these results indicate that direct interactions between IRAP ligands and sst2A receptors are 483 
unlikely.  484 
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 485 
IRAP knockdown also accelerates sst2A receptor recycling in hippocampal 486 
neurons 487 
To confirm the specificity of IRAP effects on sst2A receptor trafficking, we next aimed to 488 
silence IRAP expression in hippocampal neurons through lentiviral-mediated RNA interference. 489 
The protein expression level of IRAP was analyzed by semi-quantitative laser scanning confocal 490 
microscopy in individual transduced neurons (Fig. 8a,b). Data revealed a significant inhibition of 491 
IRAP expression by 3 separate IRAP-targeting shRNAs as compared to control shRNA (IRAP 492 
LV-shRNA1: -76%, IRAP LV-shRNA2: -70%, IRAP shRNA3: -60%; Fig. 8b). This selective 493 
down-regulation of IRAP had no effect on the targeting of the sst2A receptor to the plasma 494 
membrane or on the capacity of the receptor to internalize after OCT stimulation. Importantly, 495 
when we analyzed the recycling of the receptor at the time point 45 min after OCT washout (Fig. 496 
9a,b; chosen on the basis of pharmacological experiments for which the difference between Ang 497 
IV-treated and respective control neurons was the highest), we found that the density of the 498 
receptor at the plasma membrane was significantly higher in neurons transduced with IRAP-499 
targeting shRNAs than in neurons transduced with control shRNA (IRAP LV-shRNA1: +56%, 500 
IRAP LV-shRNA2: +62%, IRAP shRNA3: +53%, Fig. 9b). These results suggest that reduction 501 
of IRAP expression has shortened the time of recycling of internalized receptors to the plasma 502 
membrane and that IRAP is therefore a negative regulator of sst2A receptor recycling. 503 
 504 
Intra-hippocampal Ang IV or LVV-H7 administration is anticonvulsive in the rat 505 
focal pilocarpine model 506 
To further analyze whether a faster recovery of internalized sst2A receptors at the 507 
plasma membrane in response to IRAP ligands could be relevant in vivo, we next studied the 508 
effects of intra-hippocampal administration of Ang IV and LVV-H7 in a rat model of focal 509 
seizures. Indeed, an increase in SRIF immunoreactivity and secretion is known to occur in 510 
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epileptic hippocampal tissues (Tallent and Qiu, 2008) and several studies argue for a 511 
concomitant internalization of the sst2A receptors (Csaba et al., 2004; Csaba et al., 2005). 512 
Intra-hippocampal perfusion of 10 mM pilocarpine via a microdialysis probe induced a 513 
range of behavioral changes including wet dog shakes, typically beginning within 20 min 514 
following the start of pilocarpine administration. These changes progressively evolved into bouts 515 
of staring, stereotypical mouth and facial movements, forelimb clonus, and rearing. The 516 
behavioral changes correlated with electrocorticographic seizures, as previously demonstrated 517 
(Meurs et al., 2008). Pilocarpine-treated animals received intra-hippocampal co-perfusions of 1 518 
or 10 µM of the IRAP ligands Ang IV or LVV-H7 through a microdialysis probe. The maximum 519 
seizure severity score (SSS) (Fig. 10a,b; Bin 12) of animals perfused with 1 µM Ang IV or 1 µM 520 
LVV-H7 was not significantly different from the maximum SSS of animals in the pilocarpine 521 
control group. Similarly, the mean total seizure severity score (TSSS) of animals treated with 1 522 
µM Ang IV or 1 µM LVV-H7 were not significantly different from the mean TSSS observed in the 523 
pilocarpine control group. By contrast, the maximum SSS (Fig. 10a,b; Bin 12) for animals treated 524 
with 10 µM Ang IV or 10 µM LVV-H7 were significantly lower compared to the SSS in animals of 525 
the pilocarpine control group (Fig. 10a,b). In animals treated with 10 µM Ang IV or 10 µM LVV-526 
H7, only minor seizure-related behavioral changes were observed, such as wet dog shakes and 527 
less commonly staring. Correspondingly, the mean TSSS of animals treated with 10 µM Ang IV 528 
or 10 µM LVV-H7 were significantly lower compared to the mean TSSS observed in the 529 
pilocarpine control group (Fig. 10a,b). Taken together, these results demonstrate that IRAP 530 
ligands, at a microdialysis probe perfusion concentration of 10 µM, display anticonvulsant 531 
effects.  532 
 533 
The anticonvulsant effects of IRAP ligands are mediated by the sst2A receptor 534 
To further analyze whether the anticonvulsant properties of IRAP could be mediated by 535 
the sst2A receptor, we next studied the effect of intra-hippocampal co-administration of sst2A 536 
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receptor antagonists and IRAP ligands in the same limbic seizure model. The sst2A receptor 537 
antagonists cyanamid 154806 or BIM-23627 did not significantly affect seizure severity 538 
compared to the pilocarpine control groups when perfused in the hippocampus at a 539 
concentration of 0.1 µM (Fig. 11a,b). However, seizure severity was significantly higher in 540 
animals perfused with 0.1 µM cyanamid 154806 followed by 10 µM Ang IV (Fig. 11a) or 10 µM 541 
LVV-H7 (Fig. 11c) and 0.1 µM BIM-23627 followed by 15 µM Ang IV (Fig. 11b) compared to Ang 542 
IV and LVV-H7 alone (Fig. 11a-c). Altogether, these experiments demonstrate that sst2A 543 
receptor antagonists abolish the anticonvulsant effects of Ang IV and LVV-H7 and that the sst2A 544 
receptor is thus a key factor for the anticonvulsant effects mediated by the IRAP ligands. 545 
 546 
The anticonvulsant effects of IRAP ligands are independent of angiotensin AT1 547 
and µ/κ opioid receptor activation 548 
Because Ang IV and LVV-H7 were previously characterized as low affinity angiotensin 549 
AT1 (Yang et al., 2008; De Bundel et al., 2009; De Bundel et al. 2010) and opioid µ/κ receptor 550 
(Zhao et al., 1997; Lee et al., 2001) agonists, we therefore investigated the possible involvement 551 
of these receptor subtypes in the anticonvulsant effects of Ang IV and LVV-H7. The angiotensin 552 
AT1 receptor antagonist candesartan and the opioid µ/κ receptor antagonist naltrexone, 553 
perfused into the hippocampus at a concentration of 0.1 µM, had no significant effect on seizure 554 
severity compared to the pilocarpine control group (Fig. 12a,b). Furthermore, pre-treatment with 555 
candesartan or naltrexone did not abolish the anticonvulsive effect of Ang IV and LVV-H7 as 556 
compared to the pilocarpine control group (Fig. 12a,b).  557 
 558 
IRAP ligands have no effect on extracellular hippocampal SRIF levels 559 
Anticonvulsant effects of IRAP ligands could be due, in addition to their effects on sst2A 560 
receptor recycling, to an increase in hippocampal SRIF concentrations through inhibition of its 561 
degradation, as reported in one in vitro study in PC12 cells (Matsumoto et al., 2001). We 562 
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therefore analyzed the effects of intra-hippocampal administration of anticonvulsant 563 
concentrations of Ang IV or LVV-H7 on hippocampal SRIF levels. The mean baseline 564 
concentrations of SRIF in hippocampal microdialysates was 0.80±0.15 nM. Intra-hippocampal 565 
perfusion of 10 µM Ang IV or 10 µM LVV-H7 had no effect on baseline SRIF levels of the 566 
hippocampal microdialysates (Fig. 13). The inhibition of enzymatic SRIF degradation is therefore 567 
not implicated in the mechanism of anticonvulsant action of the IRAP ligands. 568 
 569 
Ang IV potentiates the anticonvulsive effect of SRIF 570 
We next investigated whether intrahippocampal administration of the IRAP ligand Ang IV could 571 
potentiate the anticonvulsive effect of SRIF (Aourz et al., 2011). We found that 1 µM Ang IV and 572 
0.1 µM SRIF had no effect on pilocarpine-induced seizures. Co-perfusion of both peptides in the 573 
same concentration suppressed behavioral seizures (Fig 14a) and EEG seizures (Fig 14b-g). 574 
These data clearly demonstrate that Ang IV potentiates the anticonvulsive effect of SRIF in the 575 
focal pilocarpine model, potentially by increasing the availability of sst2A receptors at the 576 
membrane of hippocampal neurons. 577 
 578 
IRAP ligands increase the density of membrane-associated sst2A receptors in vivo 579 
following evocation of a limbic seizure event 580 
To further demonstrate that Ang IV antiepileptic effects are driven by an increase of 581 
membrane-associated receptors in vivo, as demonstrated in vitro, the density of sst2A receptors 582 
was quantified by immunogold electron microscopy in CA1 pyramidal cell dendrites of 583 
pilocarpine-injected animals treated or not with an anticonvulsive dose of Ang IV (Fig. 15a-d). 584 
Whereas in the pilocarpine control group, 70% of immunoparticles were found in intracellular 585 
compartments and 30% membrane-associated (Fig. 15a,c), in the animals receiving intra-586 
hippocampal perfusion of Ang IV and pilocarpine, the distribution was reversed: 30% of 587 
immunoparticles were intracellular and 70% membrane-associated (Fig. 15b,c). The latter 588 
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distribution is close to that we have previously reported in naive animals, i.e. 20% intracellular 589 
and 80% membrane-associated (Csaba et al., 2007). Quantitative analysis revealed that the 590 
density of sst2A receptors at the plasma membrane was significantly higher in Ang IV-treated 591 
animals as compared to controls (Fig. 15d). Conversely, the density of intracellular sst2A 592 
receptor immunoparticles was significantly lower in Ang IV-treated animals as compared to 593 
controls (Fig. 15d). These results suggest that, as demonstrated in vitro, Ang IV accelerates the 594 
recycling of internalized receptors induced by SRIF release during the evoked seizure process. 595 
Together with the fact that sst2A receptor antagonists prevent the anticonvulsive effects 596 
mediated by Ang IV or LVV-H7, the recovery of the sst2A receptors at the plasma membrane 597 
appears as the key mechanism involved in the anticonvulsive effects mediated by IRAP ligands. 598 
599 
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Discussion 600 
 601 
The life cycle of GPCRs includes biosynthesis in the endoplasmic reticulum, maturation 602 
in the Golgi and transport to the cell surface followed by signal transduction at the plasma 603 
membrane and often internalization. Additional signaling can also occur in early endosomes as 604 
recently demonstrated (Irannejad et al., 2013). GPCR-interacting proteins have been 605 
demonstrated to play a critical role along these different phases (von Zastrow and Williams, 606 
2012). However, much remains to be learnt about mechanisms that regulate post-endocytic 607 
sorting and recycling of GPCRs. As documented in our study, the insulin-regulated 608 
aminopeptidase, IRAP, appears as a new modulator of GPCR trafficking by affecting the kinetics 609 
of the sst2A receptor recycling after ligand activation in neurons. Trans-modulation of the 610 
recycling of a GPCR through ligand binding to a non-GPCR membrane protein, has, to our 611 
knowledge, not yet been described. Trans-effects on GPCR trafficking were until now only 612 
described through oligomerization of receptors (von Zastrow and Williams, 2012), which mostly 613 
affect the endocytosis process. Importantly, our study also demonstrates that modulating the 614 
recycling of a particular receptor can indeed impact its physiological fate and therefore present a 615 
potential therapeutic value. 616 
Within the hippocampus, the major SRIF receptor subtype, the sst2A receptor, is 617 
localized at post-synaptic sites of the principal cells (Dournaud et al., 1996; Schindler et al., 618 
1997; Csaba et al., 2007). Although this receptor appears to be an attractive therapeutic target 619 
in epilepsy, it rapidly internalizes in vivo before a slow recycling process (Csaba et al., 2007; 620 
Lelouvier et al., 2008). This long route has been suggested to have an impact on sst2A receptor-621 
mediated signaling when, in pathophysiological conditions such as epilepsy, a high and chronic 622 
release of SRIF occurs (Vezzani and Hoyer, 1999). Indeed, a decreased density of this receptor 623 
subtype has been demonstrated in both rat and human epileptic dentate gyrus (Csaba et al., 624 
2004; Csaba et al., 2005). Importantly, our present data suggest that down-regulation of the 625 
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sst2A receptor can be counteracted and consequently can increase endogenous SRIF 626 
anticonvulsant properties. We first found that internalized receptors travel massively through an 627 
intra-cytoplasmic pool of IRAP-positive vesicles. IRAP has been proposed to serve as a cargo of 628 
cell-specific storage vesicles and as an active player in their trafficking (Saveanu and van 629 
Endert, 2012). Our findings support this notion since we demonstrate here that IRAP regulates 630 
either directly or indirectly the sorting of sst2A receptors from cytoplasmic vesicles to the plasma 631 
membrane. Secondly, we established that the IRAP ligand Ang IV or the knockdown of IRAP 632 
expression both accelerate the recycling of sst2A receptors after their endocytosis in 633 
hippocampal cells. These observations suggest a possible trans-modulation of sst2A receptor 634 
trafficking by IRAP. We then showed that the anticonvulsive effects of both Ang IV and the 635 
structurally distinct peptidergic IRAP ligand LVV-H7 were reversed by intra-hippocampal co-636 
administration of two structurally different sst2A receptor antagonists, cyanamid 154806 and 637 
BIM-23627. These results unequivocally confirm the involvement of the sst2A receptor in the 638 
anticonvulsive effects of the IRAP ligands. Moreover, we found that a low dose of Ang IV, which 639 
does not exert anticonvulsive effects as such, potentiates the anticonvulsive action of SRIF. We 640 
then asked whether Ang IV and LVV-H7 may exert their anticonvulsive effects through putative 641 
inhibition of SRIF degradation via IRAP (Matsumoto et al., 2001). We have established that 642 
perfusion of anticonvulsive concentrations of Ang IV or LVV-H7 into the hippocampus had no 643 
effect on local SRIF levels. This suggests that IRAP is not involved in SRIF degradation in the 644 
rodent brain. Other enzymes, such as endopeptidase-24.11 (Sakurada et al., 1990; Barnes et 645 
al., 1995) or endopeptidase-24.15 and 24.16 (Dahms and Mentlein, 1992), may be more 646 
important for SRIF degradation. Consequently, we rule out the “enzyme hypothesis” as a 647 
mechanism of action in our limbic seizure model. Importantly, using immunogold electron 648 
microscopy, we further demonstrate that Ang IV increased in vivo the availability of membrane-649 
associated sst2A receptors. Taken together, our results bring us to the conclusion that IRAP 650 
ligands favor a rapid recycling and resensitization of sst2A receptors following their 651 
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internalization and enhance endogenous SRIF inhibitory effects on seizure activity by increasing 652 
the density of functional receptors at the plasma membrane. These results are in agreement with 653 
studies using the ß2 adrenergic receptor (Pippig et al., 1995; Vistein and Puthenveedu, 2013) or 654 
the Human G Protein-Coupled Receptor 17 (Daniele et al., 2011) demonstrating that recycled 655 
receptors resensitize rapidly. 656 
In the hippocampal formation, SRIF interneurons and the sst2A receptor, which is highly 657 
expressed in the dendritic fields of granular and pyramidal cells, are well poised to regulate 658 
neuronal hyperexcitability (Johansson et al., 1984; Tallent and Qiu, 2008). Hilar SRIF inhibitory 659 
interneurons and their axons that terminate on the distal dendrites of granule cells are positioned 660 
to inhibit granule cells at the perforant path inputs, a major excitatory pathway to the 661 
hippocampus. SRIF fibers are present in the hilus, suggesting that SRIF neurons also modulate 662 
hilar neurons (Leranth et al., 1990; Lubke et al., 1998). SRIF axons are also localized throughout 663 
the CA1-CA3 regions, being enriched in stratum lacunosum moleculare (Johansson et al., 664 
1984). Distinct inhibitory actions at the cellular level in rat CA1 pyramidal neurons were 665 
demonstrated for SRIF. It increases two different types of K+ currents, the voltage-sensitive M-666 
current (Moore et al., 1988; Schweitzer et al., 1990) and a voltage-insensitive leak current 667 
(Schweitzer et al., 1998). Postsynaptic hyperpolarization and reduced excitatory postsynaptic 668 
currents of CA1-3 pyramidal neurons by SRIF have also been reported (Tallent and Siggins, 669 
1997, 1999). Taken together, these studies and our present results emphasize the importance of 670 
the hippocampal somatostatinergic network, which includes the availability of functional sst2A 671 
receptors at the plasma membrane for dampening neuronal hyperexcitability. 672 
Although beyond the scope of the present study, it would be of interest to decipher the 673 
mechanisms by which IRAP is able to regulate the recycling of the sst2A receptor. In CHO-K1 674 
and HEK 293 cells, iodinated Ang IV induced internalization of IRAP which appears to be 675 
clathrin-mediated (Demaegdt et al., 2008). Ligand-induced internalization and recycling of IRAP 676 
has also been suggested in neurons (Fernando et al., 2008). In hippocampal cells treated with 677 
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Ang IV, we did not observe a time-dependent accumulation of IRAP immunoreactivity within 678 
intracytoplasmic vesicles. This suggests that intracellular stores of IRAP are constantly driven to 679 
the cell surface to replace internalized IRAP, and that the IRAP exocytosis rate is higher in the 680 
presence of its ligands. Because internalized sst2A receptors travel through IRAP-containing 681 
vesicles, one can hypothesize that the rate of receptor exocytosis is indirectly dependent upon 682 
the presence of IRAP ligands, i.e. sst2A receptors recycle faster in cells or tissue incubated with 683 
Ang IV or LVV-H7. If this is the case, effects of IRAP ligands would not be specific for the sst2A 684 
receptor but could also modulate other types of receptors that internalize and recycle through an 685 
IRAP/TGN compartment. Most interestingly, Ang IV has been shown to reverse the kindling-686 
induced down-regulation of dopaminergic D1 and D2 receptors in the basal ganglia 687 
(Tchekalarova et al., 2004), two receptors which are well known to internalize in neurons 688 
(Dumartin et al., 1998; Skinbjerg et al., 2010; Lane et al., 2012). Thus IRAP ligands, in addition 689 
to their potential for modulating limbic seizures, might also represent appealing therapeutic tools 690 
in neurological diseases or following pharmacological treatments in which down-regulation of 691 
GPCRs could occur (Bezard et al., 2001; Gainetdinov et al., 2004; Williams et al., 2013). 692 
Although the above described mechanism by which IRAP ligands could impact on sst2A 693 
receptor intracellular trafficking is a likely starting hypothesis, the cellular events involved could 694 
be difficult to decipher. In insulin-sensitive cells, IRAP trafficking itself is far from being 695 
understood, despite a large number of studies (Albiston et al., 2007). In addition, IRAP and the 696 
sst2A receptor both interact through their intra-cytoplasmic domain with several proteins 697 
involved in vesicle trafficking, tethering and membrane anchoring (Albiston et al., 2007; Watson 698 
et al., 2008; Csaba et al., 2012). Interestingly, IRAP knockdown in adipocytes increase plasma 699 
membrane GLUT4 levels due to increase of exocytosis (Jordens et al., 2010). Regarding our 700 
present results showing that IRAP knockdown increases the recycling of the receptor to the 701 
plasma membrane, it appears that IRAP could be a negative regulator of the exocytosis pathway 702 
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in different cell types. Further studies in neuronal cells are mandatory to shed lights on the 703 
molecular and cellular mechanisms implicated in this process. 704 
In conclusion, the present study demonstrates that two structurally different peptidergic 705 
IRAP ligands protect against limbic seizures in rats. These anticonvulsive effects do not result 706 
from the inhibition of the enzymatic activity of IRAP and subsequent prevention of SRIF 707 
degradation. We demonstrate that IRAP, following ligand binding, trans-regulates the recycling 708 
process of the sst2A receptor and increases the availability of this inhibitory receptor at the 709 
plasma membrane. This represents a novel mechanism by which GPCR transmission can be 710 
regulated and further demonstrates that IRAP is a potential therapeutic target for the treatment 711 
of epilepsy. Whether IRAP could modulate the down-regulation of other types of GPCRs, thus 712 
displaying additional therapeutic interests, will represent intriguing issues for future studies. 713 
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Legends 929 
 930 
Figure 1. Neurons expressing the sst2A receptor also display IRAP immunoreactivity in 931 
the rat hippocampal formation. a) In control rats, diffuse sst2A receptor immunoreactivity is 932 
observed in the strata oriens (Or) and radiatum (Rad) of CA1-3 and the molecular layer (Mol) of 933 
dentate gyrus (DG). b) After intra-hippocampal injection of octreotide (OCT), sst2A receptor-934 
immunoreactive neurons are detected in the pyramidal cell layer (Py) of CA1-3 and granular 935 
layer (Gr) of DG. c) IRAP-immunoreactivity is located in the principal cell layers of the 936 
hippocampal formation. d) In the CA1 of control rats, double-labeling immunohistochemistry 937 
reveals that IRAP is predominantly localized in pyramidal cell bodies (Py), whereas sst2A 938 
receptor immunoreactivity is diffusely distributed in strata oriens (Or) and radiatum (Rad). Inset 939 
shows sst2A receptor immunoreactivity in the pyramidal cells layer. e-g) In OCT-injected rats, 940 
double-labeling immunohistochemistry reveals colocalization of internalized sst2A receptor and 941 
IRAP in pyramidal neurons of CA1. Note that all hippocampal sst2A receptor-immunoreactive 942 
neurons are IRAP-positive. Only a subpopulation of IRAP-immunoreactive neurons is sst2A 943 
receptor-positive. Similar stainings were found in three different OCT-injected rats (three 944 
sections per animal). Scale bars: a-c, 400 μm; d-g, 40 μm.  945 
 946 
Figure 2. Kinetics of sst2A receptor internalization in primary hippocampal neurons. In 947 
control neurons, the sst2A receptor immunoreactivity is predominantly located at the surface of 948 
perikarya and proximal dendrites. Conversely, IRAP immunofluorescence is mainly confined to 949 
intracellular vesicles overlapping with trans-Golgi network marker TGN38. Little colocalization is 950 
thus observed between sst2A receptor and IRAP. Treatment with the sst2A receptor agonist 951 
octreotide for 5, 10 or 20 min results in a massive redistribution of sst2A receptor 952 
immunoreactivity from the cell surface into intracellular vesicles, where it is colocalized with 953 
IRAP (yellow pseudocolor signal on sst2A/IRAP merged images) and TGN38 (white pseudocolor 954 
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signal on sst2A/IRAP/TGN38 merged images). Thirty neurons/group were analyzed from 3 955 
independent experiments. OCT, octreotide. Scale bars: 10 μm. 956 
 957 
Figure 3. Internalized sst2A receptor colocalizes with IRAP in primary hippocampal 958 
neurons. The sst2A receptor immunoreactivity is confined to bright fluorescent granules in the 959 
cytoplasm of octreotide-treated neurons and colocalizes with IRAP-positive vesicles (arrows) as 960 
illustrated by high resolution confocal microscopy in three different neurons. Scale bars: 2 μm. 961 
 962 
Figure 4. Kinetics of sst2A receptor recycling in primary hippocampal neurons. Fifteen 963 
minutes after agonist washout, only intracellular sst2A receptor immunoreactivity is apparent. 964 
Thirty min after OCT washout, the large majority of sst2A receptor immunofluorescence is still 965 
intracellular. However, membrane-associated receptors become apparent in perikarya and 966 
proximal dendrites. From 60 to 120 min after agonist washout, the surface sst2A receptor 967 
labeling becomes more and more intense. In parallel, the intensity of intracellular 968 
immunofluorescence gradually decreases. At 180 min after OCT washout, the distribution of 969 
sst2A receptor immunoreactivity is very similar to control conditions (i.e. before agonist-induced 970 
internalization of the receptor). The colocalization of sst2A receptor with IRAP (yellow 971 
pseudocolor signal on sst2A/IRAP merged images) and trans-Golgi network marker TGN38 972 
(white pseudocolor signal on sst2A/IRAP/TGN38 merged images) is important at 30 min after 973 
octreotide washout and gradually decreases from 60 to 180 min. Thirty neurons/group were 974 
analyzed from 3 independent experiments. OCT, octreotide. Scale bars: 10 μm. 975 
 976 
Figure 5. IRAP ligands accelerate sst2A receptor recycling in hippocampal neurons. At 45 977 
min after OCT washout, sst2A receptor immunoreactivity is localized in the cytoplasm, 978 
overlapping with the trans-Golgi network marker TGN38, as well as at the cell surface in a form 979 
of a fluorescent ring (arrows). Note that the surface sst2A receptor labeling is more intense in 980 
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the Ang IV-treated neuron than in the PBS control. OCT, octreotide; PBS, phosphate-buffered 981 
saline. Scale bars: 10 μm.  982 
 983 
Figure 6. Analysis of sst2A receptor recycling in hippocampal neurons. a) For 984 
semiquantitative analysis, a single optical section is acquired from the neuronal cell body at a z-985 
axis level where the sst2A receptor labeling at the plasma membrane is identified as a line-like 986 
ring in the green channel around the TGN38 labeling of the red channel. Scale bar: 10 μm. b) 987 
Semiquantitative analysis reveals a significantly higher sst2A receptor immunofluorescence at 988 
the plasma membrane 30, 45 and 60 min after OCT washout in the Ang IV-treated neurons as 989 
compared to the respective PBS controls (upper panel). The sst2A receptor signal intensity is 990 
higher at the plasma membrane 45 min after OCT or SRIF washout in the Ang IV-treated group 991 
as compared to the respective PBS controls. Note, that no significant difference is detected 992 
between respective OCT- and SRIF-treated groups (lower panel). Thirty neurons/group were 993 
analyzed from 3 independent experiments. Values are expressed in relation to an arbitrary unit 994 
(100%) of the control value (PBS w/o agonist). ***p < 0.001; ns, not significant (ANOVA followed 995 
by Bonferroni's Multiple Comparison Test). Ang IV, angiotensin IV; OCT, octreotide; PBS, 996 
phosphate-buffered saline. 997 
 998 
Figure 7. IRAP ligands do not bind to the sst2A receptor in stably transfected CHO-K1 999 
cells. The specific binding of Ang IV (a) and LVV-H7 (b) to sst2A receptors in CHO-K1 cells was 1000 
investigated by incubating these cells with increasing concentrations (10-9 M to 10-5 M) of IRAP 1001 
ligands and 0.5 nM radiolabeled SRIF. In four independent experiments, the 125I-labeled SRIF 1002 
and IRAP ligands competed for binding to sst2A receptors, after which the number of counts per 1003 
minute were measured. The results are shown as the percentage of 125I-labeled SRIF binding to 1004 
sst2A receptors. Ang IV, angiotensin IV; LVV-H7, LVV-Hemorphin 7. 1005 
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 1006 
Figure 8. IRAP-targeting shRNAs decreases IRAP immunoreactivity in hippocampal 1007 
neurons. a) Using TurboGFP lentiviral particles with three IRAP-targeting shRNAs (IRAP LV-1008 
shRNA1-3) and a non-targeting control (NT LV-shRNA), neuronal transduction is demonstrated 1009 
by the presence of the TurboGFP signal (green). In neurons transduced with non-targeting LV-1010 
shRNA, IRAP immunoreactivity is mainly confined to vesicles in the cell bodies and proximal 1011 
dendrites (red). Note that in neurons transduced with IRAP-targeting shRNA, the intensity of 1012 
IRAP immunofluorescence is low. Scale bars: 10 μm. b) Semiquantitative analysis reveals that 1013 
the intensity of IRAP immunoreactivity in the IRAP LV-shRNA1-3 groups is significantly lower as 1014 
compared to the NT LV-shRNA controls. Thirty neurons/group were analyzed from 3 1015 
independent experiments. ***p < 0.001 (ANOVA followed by Bonferroni's Multiple Comparison 1016 
Test).  1017 
Figure 9. IRAP knockdown increases sst2A receptor recycling in hippocampal neurons. a) 1018 
Using TurboGFP lentiviral particles with three IRAP-targeting shRNAs (IRAP LV-shRNA1-3) and 1019 
a non-targeting control (NT LV-shRNA), neuronal transduction is demonstrated by the presence 1020 
of the TurboGFP signal. At 45 min after agonist washout, in neurons transduced with both non-1021 
targeting and IRAP-targeting shRNA, the sst2A receptor immunoreactivity is localized in the 1022 
cytoplasm, overlapping with the trans-Golgi marker TGN38. Receptors are also localized at the 1023 
cell surface (arrows). Note, however, that the intensity of the surface sst2A receptor labeling is 1024 
higher in neurons transduced with IRAP LV-shRNAs than those with the NT LV-shRNA control. 1025 
Scale bars: 10 μm. b) Semiquantitative analysis reveals that the intensity of sst2A receptor 1026 
immunoreactivity at the plasma membrane 45 min after OCT washout is significantly higher in 1027 
the IRAP LV-shRNA1-3 groups as compared to the NT LV-shRNA control. Thirty neurons/group 1028 
were analyzed from 3 independent experiments. Values are expressed in relation to an arbitrary 1029 
unit (100%) of the control value (NT LV-shRNA). ***p < 0.001 (ANOVA followed by Bonferroni's 1030 
Multiple Comparison Test). OCT, octreotide. 1031 
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 1032 
Figure 10. IRAP ligands display anticonvulsive properties in the rat focal pilocarpine 1033 
model. Time profiles of seizure severity scores (SSS) are shown with total seizure severity 1034 
score (TSSS) in the inserts. Both Ang IV (a) and LVV-H7 (b) treatments at 10 μM concentration 1035 
result in a significantly lower SSS and TSSS. **p < 0.01; ***p < 0.001 vs. pilocarpine control 1036 
group (SSS: two-way ANOVA followed by Dunnett’s Multiple Comparison Test; TSSS: ANOVA 1037 
followed by Bonferroni's Multiple Comparison Test). Ang IV, angiotensin IV; LVV-H7, LVV-1038 
Hemorphin 7. 1039 
 1040 
Figure 11. Antagonists of the sst2A receptor prevent the anticonvulsive effect of Ang IV 1041 
and LVV-H7 in the rat focal pilocarpine model. The sst2A receptor antagonist cyanamid 1042 
154806 (a and c) or BIM-23627 (b) reverse the effect of Ang IV (a, b) and LVV-H7 (c) on total 1043 
seizure severity score (TSSS). *p < 0.05; **p < 0.01 between groups (ANOVA followed by 1044 
Bonferroni's Multiple Comparison Test). Ang IV, angiotensin IV; LVV-H7, LVV-Hemorphin 7.  1045 
 1046 
Figure 12. Angiotensin AT1 (a) and μ/κ (b) receptors are not implicated in the 1047 
anticonvulsive effect of Ang IV and LVV-H7 in the focal pilocarpine model. AT1 receptor 1048 
antagonist Candesartan (a) and the opioid µ/k receptor antagonist Naltrexone (b) have no 1049 
significant effect on seizure severity as compared to the pilocarpine control group. Furthermore, 1050 
pre-treatment with Candesartan or Naltrexone does not abolish the anticonvulsive effect of Ang 1051 
IV. **p < 0.01; ns, not significant compared to the pilocarpine control group (ANOVA followed by 1052 
Bonferroni's Multiple Comparison Test). TSSS, total seizure severity score; Ang IV, angiotensin 1053 
IV; LVV-H7, LVV-Hemorphin 7. 1054 
 1055 
Figure 13. Administration of Ang IV and LVV-H7 does not decrease hippocampal SRIF 1056 
concentration. Administration of Ang IV or LVV-H7 has no effect on SRIF concentration of 1057 
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hippocampal microdialysates (two-way ANOVA followed by Bonferroni’s Multiple Comparison 1058 
Test: Ang IV or LVV-H7 vs. aCSF control group). aCSF, artificial cerebrospinal fluid; Ang IV, 1059 
angiotensin IV; LVV-H7, LVV-Hemorphin 7. 1060 
 1061 
Figure 14. Ang IV potentiates the anticonvulsive effect of SRIF in the focal pilocarpine 1062 
model. A combination of subthreshold concentrations (i.e. ineffective on pilocarpine-induced 1063 
seizures) of Ang IV (1 µM) and SRIF (0.1 µM) significantly reduces behavioral seizures (a) 1064 
compared to the pilocarpine control group. In rats treated with both Ang IV and SRIF, EEG 1065 
seizure duration is not significantly different (b), while the latency to first EEG seizure is 1066 
significantly higher (c) compared to the pilocarpine control group. The TSSS is positively 1067 
correlated with EEG seizure duration (c) and negatively correlated with EEG seizure latency (d). 1068 
Representative EEG traces are shown in (f) with (g) illustrating baseline EEG activity (left 1069 
panels) and typical spike-wave activity 40 min following the onset of pilocarpine administration 1070 
(right panels). *p < 0.05; **p < 0.01 compared to the pilocarpine control group (ANOVA followed 1071 
by Bonferroni's Multiple Comparison Test). TSSS, total seizure severity score; Ang IV, 1072 
angiotensin IV; LVV-H7, LVV-Hemorphin 7. 1073 
 1074 
Figure 15. Ang IV increases in vivo the density of sst2A receptors at the plasma 1075 
membrane in pilocarpine-treated rats. a,b) In pilocarpine control rats, many sst2A receptor 1076 
immunoparticles are intracellular (arrows) in dendrites (a) and dendritic spines (inset of a) of 1077 
CA1 pyramidal neurons. In the pilocarpine group which received intra-hippocampal perfusion of 1078 
Ang IV, numerous sst2A receptor immunoparticles are located at the plasma membrane 1079 
(arrowheads) of dendrites (b) and dendritic spines (inset of b) of CA1 pyramidal neurons. Scale 1080 
bar: 500 nm. c) In pilocarpine control rats, the largest proportion of sst2A receptor 1081 
immunoparticles are intracellular in CA1 pyramidal cell dendrites, only 28.6% of them are 1082 
associated with the plasma membrane. By contrast, in the pilocarpine group treated with Ang IV, 1083 
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70.5% of sst2A receptor immunoparticles are at the plasma membrane of CA1 pyramidal cell 1084 
dendrites. d) Statistical analysis reveals that the density of immunoparticles is significantly higher 1085 
at the plasma membrane and lower intracellularly in the Ang IV-treated pilocarpine group as 1086 
compared to the pilocarpine controls. Note that the total number of immunoparticles is not 1087 
different between the two groups. Ten dendrites/animal were analyzed in 3 control and Ang IV-1088 
treated rats. Values are expressed in relation to an arbitrary unit (100%) of the control values. 1089 
**p < 0.01; ***p < 0.001; ns, not significant (Mann-Whitney U test). Ang IV, angiotensin IV; IC, 1090 
intracellular; PM, plasma membrane. 1091 















